Transform Wealth LLC Buys 74 Shares of Johnson & Johnson (NYSE:JNJ)

Transform Wealth LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,335 shares of the company’s stock after acquiring an additional 74 shares during the period. Transform Wealth LLC’s holdings in Johnson & Johnson were worth $540,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Innealta Capital LLC acquired a new stake in Johnson & Johnson during the second quarter worth $27,000. MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson in the second quarter worth about $43,000. Fairfield Financial Advisors LTD bought a new position in Johnson & Johnson during the second quarter worth about $46,000. Fairway Wealth LLC raised its holdings in shares of Johnson & Johnson by 217.1% in the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after buying an additional 228 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $49,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday. Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.93.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $164.28 on Thursday. The firm has a market capitalization of $395.37 billion, a P/E ratio of 10.24, a PEG ratio of 2.65 and a beta of 0.52. The business has a 50-day moving average of $162.81 and a 200-day moving average of $154.59. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.